おすすめの製品
アッセイ
≥98% (HPLC)
形状
powder
保管条件
desiccated
色
white to tan
溶解性
DMSO: >10 mg/mL
オーガナイザー
Schering Plough
保管温度
room temp
SMILES記法
CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O
InChI
1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
InChI Key
YPQLFJODEKMJEF-UHFFFAOYSA-N
アプリケーション
Hydroxyflutamide has been used:
- as an androgen receptor antagonist to study its effects on cardiomyocyte hypertrophy induced by dihydrtestosterone (DHT) in primary neonatal rat ventricular cardiomyocyte and rat cardio myoblast (H9c2) cells.
- as an androgen receptor antagonist for the treatment of MDA-kb2 cells to check its effect on luciferase expression.
- as an antagonist control in transcriptional activation assay.
生物化学的／生理学的作用
ヒドロキシフルタミドはARアンタゴニストです。アンドロゲンレセプター(AR)は核内ホルモンレセプターであり、転写因子としても作用します。ヒドロキシフルタミドは、1981年に発表されたアンドロゲンアンタゴニストです。ヒドロキシフルタミドはARアンタゴニストの数少ないゴールドスタンダードの1つであり、新規アンタゴニストの活性は、ヒドロキシフルタミドを基準にして測定されます。
Hydroxyflutamide plays a role in preventing the binding of 5α-dihydrotestosterone (DHT) and testosterone to the androgen receptors.
特徴および利点
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
ターゲットの組織
Respiratory system
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
H4166-VAR:
H4166-25MG:
H4166-BULK:
H4166-5MG:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
この製品を見ている人はこちらもチェック
G E Jensen et al.
SAR and QSAR in environmental research, 22(1-2), 35-49 (2011-03-11)
Three modelling systems (MultiCase®, LeadScope® and MDL® QSAR) were used for construction of androgenic receptor antagonist models. There were 923-942 chemicals in the training sets. The models were cross-validated (leave-groups-out) with concordances of 77-81%, specificity of 78-91% and sensitivity of
Renate Louw-du Toit et al.
Biochemical and biophysical research communications, 491(1), 140-146 (2017-07-18)
Progestins used in endocrine therapies bind to multiple steroid receptors and are associated with several side-effects. It is thus important to understand the relationship between steroid receptor cross-reactivity and the side-effect profile of progestins. In cell lines that express negligible
Thomas Andrieu et al.
Biochemical pharmacology, 82(11), 1651-1662 (2011-09-13)
Prostate cancer (PCa) progression is enhanced by androgen and treatment with antiandrogens represents an alternative to castration. While patients initially respond favorably to androgen ablation therapy, most experience a relapse of the disease within 1-2 years by expressing androgen receptor
M Lydka et al.
Reproduction in domestic animals = Zuchthygiene, 47(4), 635-643 (2011-11-05)
Our previous work has shown that an anti-androgen flutamide administered pre- and post-natally induced adverse effects on the epididymal morphology and function of adult boars. The present investigation is aimed to understand the effect of flutamide and its metabolite on
Seva E Kostrubsky et al.
Chemical research in toxicology, 20(10), 1503-1512 (2007-09-29)
Treatment with flutamide has been associated with clinical hepatotoxicty. The toxicity, metabolism,and transport of flutamide were investigated using cultured human hepatocytes. Flutamide and its major metabolite, 2-hydroxyflutamide, caused an inhibition of taurocholate efflux in human hepatocytes with an IC50=75 microM
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）